Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malin Wickström

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Journal of the Endocrine Society|February 8, 2024
Humanin Treatment Protects Against Venetoclax-Induced Bone Growth Retardation in <i>Ex Vivo</i> Cultured Rat BonesLilly Velentza, Malin Wickström, Per Kogner, et al.
Investigational New Drugs|October 9, 2007
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitroMalin Wickström, Caroline Haglund, Henrik Lindman, et al.
Scientific Reports|May 17, 2023
Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growthLilly Velentza, Malin Wickström, Per Kogner, et al.
Molecular Cancer Therapeutics|May 24, 2013
Alternative cytotoxic effects of the postulated IGF-IR inhibitor picropodophyllin in vitroXuping Wu, Linda Sooman, Malin Wickström, et al.
International Journal of Cancer|July 1, 2011
Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivoLova Segerström, Ninib Baryawno, Baldur Sveinbjörnsson, et al.
Journal of Natural Products|November 10, 2009
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugsJenny Felth, Linda Rickardson, Josefin Rosén, et al.
Journal of the National Cancer Institute|March 4, 2014
Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatmentEmma Eriksson, Malin Wickström, Lova Segerström Perup, et al.
Journal of Drug Targeting|December 12, 2003
Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1Joachim Gullbo, Malin Wickström, Marcus Tullberg, et al.
Biochemical Pharmacology|October 10, 2006
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patientsMalin Wickström, Katarina Danielsson, Linda Rickardson, et al.
Anticancer Research|January 2, 2020
Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell LinesStefan Holzhauser, Monika Lukoseviciute, Teodora Andonova, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Journal of the Endocrine Society|February 8, 2024
Humanin Treatment Protects Against Venetoclax-Induced Bone Growth Retardation in <i>Ex Vivo</i> Cultured Rat BonesLilly Velentza, Malin Wickström, Per Kogner, et al.
Investigational New Drugs|October 9, 2007
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitroMalin Wickström, Caroline Haglund, Henrik Lindman, et al.
Scientific Reports|May 17, 2023
Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growthLilly Velentza, Malin Wickström, Per Kogner, et al.
Molecular Cancer Therapeutics|May 24, 2013
Alternative cytotoxic effects of the postulated IGF-IR inhibitor picropodophyllin in vitroXuping Wu, Linda Sooman, Malin Wickström, et al.
International Journal of Cancer|July 1, 2011
Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivoLova Segerström, Ninib Baryawno, Baldur Sveinbjörnsson, et al.
Journal of Natural Products|November 10, 2009
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugsJenny Felth, Linda Rickardson, Josefin Rosén, et al.
Journal of the National Cancer Institute|March 4, 2014
Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatmentEmma Eriksson, Malin Wickström, Lova Segerström Perup, et al.
Journal of Drug Targeting|December 12, 2003
Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1Joachim Gullbo, Malin Wickström, Marcus Tullberg, et al.
Biochemical Pharmacology|October 10, 2006
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patientsMalin Wickström, Katarina Danielsson, Linda Rickardson, et al.
Anticancer Research|January 2, 2020
Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell LinesStefan Holzhauser, Monika Lukoseviciute, Teodora Andonova, et al.
Pageof 6